Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Synthetic Biologics Inc.

www.syntheticbiologics.com

Latest From C4 Therapeutics Inc.

Deal Watch: BioLineRx, Ono, Vedantra Ink Separate Cancer Immunotherapy Pacts

BioLineRx buys Agalimmune and its alpha Gal candidate for melanoma and possibly other oncology indications. Japan's Ono signs an R&D agreement with Switzerland's Numab, while Boston biotechs Vedantra and Neon will collaborate on potential cancer vaccines.

Commercial Deals

C4 And Google's Calico Enter Mysterious Alliance On 'Diseases Of Aging'

While details are scant, the five-year collaboration will pair C4's targeted protein degradation approach with Calico's focus on diseases of aging. Privately held C4 otherwise is aiming to bring its first Degronomid candidate into the clinic in 2018.

Deals Companies

Pharmas Pursue Tech Deals To Speed Drug Development, Measure Outcomes

Deals for technology platforms allow more of a multiple-shots-on-goal approach as opposed to taking a risk with one or two candidates.

Deals Clinical Trials

Early Stage Biopharma Financings Kept Up Multibillion-Dollar Pace In 2016

Series A venture capital and seed funding rounds for biopharma firms in 2016 kept pace with the level of investment seen in 2015, excluding one major deal in 2015, laying the foundation for optimism regarding early-stage financings in 2017 for particularly innovative companies.

Financing StartUps and SMEs
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Pipex Therapeutics Inc.
  • Pipex Pharmaceuticals Inc.
  • Sheffied Pharmaceuticals Inc.
  • Adeona Pharmaceuticals Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Synthetic Biologics Inc.
  • Senior Management
  • Jeffrey Riley, Pres. & CEO
    Steven A Shallcross, CFO
    Michael Kaleko, MD, PhD, SVP, R&D
  • Contact Info
  • Synthetic Biologics Inc.
    Phone: (301) 417-4364
    9605 Medical Center Dr., Ste. 270
    Rockville, MD 20850
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register